Patients aged 18-65 years with a primary diagnosis of recurrent MDD , a Montgomery-sberg Depression Rating Scale ( MADRS ) total score 26 and a Clinical Global Impression-Severity ( CGI-S ) score 4 were randomized ( 1:1 ) to treatment with either vortioxetine or venlafaxine XR .